These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 31639425)

  • 1. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
    Wu M; Zhang P
    Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors and autophagy in cancer treatment.
    Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY
    Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR signaling and autophagy dependence for growth, survival, and therapy resistance.
    Jutten B; Rouschop KM
    Cell Cycle; 2014; 13(1):42-51. PubMed ID: 24335351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.
    Kyriakopoulou K; Kefali E; Piperigkou Z; Bassiony H; Karamanos NK
    Cell Signal; 2018 Nov; 51():99-109. PubMed ID: 30071291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.
    Berezowska S; Diermeier-Daucher S; Brockhoff G; Busch R; Duyster J; Grosu AL; Schlegel J
    Int J Mol Med; 2010 Nov; 26(5):713-21. PubMed ID: 20878094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
    Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
    Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR and NF-κB: partners in cancer.
    Shostak K; Chariot A
    Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: just way too polymorphic.
    Zbuk KM; Eng C
    Cancer Biol Ther; 2007 Jan; 6(1):112-5. PubMed ID: 17264670
    [No Abstract]   [Full Text] [Related]  

  • 15. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.
    Talukdar S; Emdad L; Das SK; Fisher PB
    Adv Cancer Res; 2020; 147():161-188. PubMed ID: 32593400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy.
    Sooro MA; Zhang N; Zhang P
    Int J Cancer; 2018 Nov; 143(9):2116-2125. PubMed ID: 29574749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling therapy resistance via the EGFR signaling pathway.
    Plattner C; Hackl H
    FEBS J; 2019 Apr; 286(7):1284-1286. PubMed ID: 30892828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of subcellularly located EGFR in autophagy.
    Li H; You L; Xie J; Pan H; Han W
    Cell Signal; 2017 Jul; 35():223-230. PubMed ID: 28428083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.